FDA clears Vivani Medical’s IND for NPM-119 in type 2 diabetes
Vivani Medical, Inc. (Nasdaq: VANI), a pioneer in biopharmaceutical innovations, has reached a pivotal milestone as the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for NPM-119, marking a significant advancement in the treatment of type 2 diabetes. This approval also lifts a previous clinical hold, allowing the initiation […]